In the last trading session, 1.69 million Lineage Cell Therapeutics Inc (AMEX:LCTX) shares changed hands as the company’s beta touched 1.25. With the company’s per share price at $0.66 changed hands at -$0.03 or -4.29% during last session, the market valuation stood at $145.46M. LCTX’s last price was a discount, traded about -143.94% off its 52-week high of $1.61. The share price had its 52-week low at $0.48, which suggests the last value was 27.27% up since then. When we look at Lineage Cell Therapeutics Inc’s average trading volume, we note the 10-day average is 2.32 million shares, with the 3-month average coming to 2.63 million.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Instantly LCTX was in red as seen at the end of in last trading. With action 4.76%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 31.32%, with the 5-day performance at 4.76% in the green. However, in the 30-day time frame, Lineage Cell Therapeutics Inc (AMEX:LCTX) is 28.14% up. Looking at the short shares, we see there were 15.94 million shares sold at short interest cover period of 35.21 days.
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Data shows that the Lineage Cell Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -28.27% over the past 6 months, a 0.00% in annual growth rate that is considerably lower than the industry average of 15.90%. Year-over-year growth is forecast to reach -7.73% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 1.62M. 3 analysts are of the opinion that Lineage Cell Therapeutics Inc’s revenue for the current quarter will be 1.36M. The company’s revenue for the corresponding quarters a year ago was 2.12M and 1.44M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -23.46%. The estimates for the next quarter sales put growth at -5.75%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.25%. The 2025 estimates are for Lineage Cell Therapeutics Inc earnings to increase by 8.33%, but the outlook for the next 5-year period is at 9.14% per year.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.44% of Lineage Cell Therapeutics Inc shares while 50.56% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 50.79%. There are 50.56% institutions holding the Lineage Cell Therapeutics Inc stock share, with BROADWOOD CAPITAL INC the top institutional holder. As of 2024-06-30, the company held 22.7798% of the shares, roughly 41.67 million LCTX shares worth $41.55 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 5.2264% or 9.56 million shares worth $9.53 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 4.42 shares estimated at $2.91 million under it, the former controlled 2.00% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.81% of the shares, roughly 4.0 shares worth around $2.64 million.
